

## BALANCE SHEETS

	March 31, 2025	March 31, 2024
	U.S. Dollars	U.S. Dollars
	Unaudited	Unaudited
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	1	1
Short-term bank deposits	-	-
Current maturities of LT Bank Deposits	-	-
Restricted short term bank deposit	-	-
Marketable Securities	-	-
Trade accounts receivable	-	-
Other receivables and prepaid expenses:		
Prepaid expenses	-	-
Deferred income taxes	-	-
Government authorities	-	-
Advances to suppliers	-	-
Derivative instruments	-	-
Intercompany balances	-	-
Other	-	-
TOTAL Other receivables and prepaid expenses	-	-
Inventories	-	-
TOTAL CURRENT ASSETS	1	1
Long Term Receivables and Other Assets	-	-
Long Term Marketable Securities	-	-
ROU Assets, net	-	-
FIXED ASSETS:		
Cost	-	-
Less - accumulated depreciation	-	-
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	-	-
DEFERRED INCOME TAXES	-	-
TOTAL ASSETS	\$ 1	\$ 1

## BALANCE SHEETS

	March 31, 2025	March 31, 2024
	U.S. Dollars	U.S. Dollars
	Unaudited	Unaudited
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Short-term bank credit	\$ -	\$ -
Current maturities of long-term debt	-	-
Accounts payable:		
Trade payables	-	-
Other current liabilities:		
Returns reserve	-	-
Due to customers	-	-
Intercompany balances	-	-
Lease Liability	-	-
Employees and payroll accruals	-	-
Current Maturities of Long Term Incentive Plan (LTIP)	-	-
Deferred revenue	-	-
Accrued income taxes	-	-
Legal and audit fees	-	-
Settlements and loss contingencies	-	-
Accrued expenses	-	-
Interest payable	-	-
Derivative instruments	-	-
Deferred taxes	-	-
Suppliers of property, plant and equipment	-	-
Payable on Purchase of treasury stock	-	-
Payable on Purchase of Marketable Securities	-	-
Other	-	-
TOTAL Other current liabilities	-	-
TOTAL CURRENT LIABILITIES	-	-
LONG-TERM LIABILITIES:		
Long-term debt, net of current maturities	-	-
Deferred income taxes	-	-
Derivative instruments	-	-
Other long-term liabilities	-	-
SHAREHOLDERS' EQUITY	1	1
	\$ 1	\$ 1

Date of approval of the  
financial statements

Zvi Albert  
Vice President, Finance and CFO

## STATEMENTS OF INCOME

	For the Year Ended	For the Year Ended
	March 31, 2025	March 31, 2024
	U.S. Dollars	U.S. Dollars
	Unaudited	Unaudited
Sales	\$ -	\$ -
Cost of sales	-	-
Gross profit	-	-
Research and development	-	-
Selling and marketing expenses	-	-
Settlements and loss contingencies	-	-
General and administrative expenses	-	-
Operating income	-	-
Financing income, net	-	-
Other income	-	-
Income before taxes on income	-	-
Taxes on income	-	-
Discontinued operation	-	-
Net income for the period before subsidiaries and dividend	-	-
Dividend income, net	-	-
Subsidiaries	-	-
Net income for the period	\$ -	\$ -

Taro Pharma Corporation, Inc.

Changes in Shareholders' Equity

	Share Capital	Additional paid in capital	Accumulated other comprehensive loss	Treasury stock	Dividend	Retained Earnings	Total Shareholders' Equity
	U.S. Dollars						
	Un-audited						
Issuance of shares	1						1
Net income							-
Balance at March 31, 2024	1	-	-	-	-	-	1
Net income							-
Balance at March 31, 2025	1	-	-	-	-	-	1